In Fy16, We Made Substantial Progress In Moving Forward Our Product Development Agenda, Capped By Significant Progress In The Fourth Quarter.

The severest forms of uveitis reoccur many times. a smaller pupil in the affected eye, The type of treatment chosen will depend on the type of inflammation present. A corticosteroid medication reduces inflammation and pain of the eye and helps to improve symptoms. When doctors diagnose and treat uveitis, they may group it in different ways. Expert Odin investing Drugs. 2009 May. 185:609-16. Does anything make your symptoms better or worse? B J Opthalmol. 2013;972:134-8. There are programs and support that can help. http://www.expertselfpublishing.com/alexanderreynoldstown/2016/08/29/helpful-tips-on-major-details-in-eye-surgery/The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. Tell your doctor before taking omega-3 fatty acids if you also take blood-thinning medications, such as aspirin, warfarin Coumadin, or clopidogrel Plavix. However, this is usually only recommended if you have repeated or severe uveitis, or if the condition is caused by certain infections. Ophthalmology. 2004 Mar. 111 3:491-500; discussion 500.

Actual results could differ materially from those anticipated, estimated, or projected in the forward-looking statements. For a more detailed discussion of risk factors that could impact our future results and financial condition, I refer you to our filings with the SEC, including our annual report on Form 10-K for the year ended June 30, 2015. We undertake no obligation to update any forward-looking statement, in order to reflect events or circumstances that may arise after this conference call. With that, I’d like to turn the call over to Paul. ——————————————————————————– Paul Ashton, pSivida Corporation – President & CEO [3] ——————————————————————————– Thank you, Lori, and welcome everyone to our discussion of our FY16 full-year and fourth-quarter results and Company update. no dataIn FY16, we made substantial progress in moving forward our product development agenda, capped by significant progress in the fourth quarter. Highlights for the quarter included 12-month follow-up that maintains the favorable results from our first Phase 3 trial for Medidur in posterior segment uveitis. Opening an IND for an investigator-sponsored study of a Durasert implant for severe knee osteoarthritis. Good results from pre-clinical testing that have allowed us to identify a product candidate to treat wet age-related macular degeneration as an implant, delivering a tyrosine kinase inhibitor.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/edited-transcript-psdv-earnings-conference-060317304.html

Leave a Reply

Your email address will not be published. Required fields are marked *